LetterLetter
Baricitinib for Refractory Eosinophilic Fasciitis: Myth or Reality?
Gang Wang, Ning Zhuo and Jingyang Li
The Journal of Rheumatology May 2022, 49 (5) 546-547; DOI: https://doi.org/10.3899/jrheum.211126
Gang Wang
1Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou;
MDNing Zhuo
2Department of Nephrology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China.
MDJingyang Li
1Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou;
MDREFERENCES
- 1.↵
- Sehgal R,
- Ernste FC,
- Eckloff S
- 2.↵
- Low AHL,
- Ng SA,
- Berrocal V, et al
- 3.↵
- Bieber T,
- Thyssen JP,
- Reich K, et al
- 4.↵In brief: new warnings for Janus kinase inhibitors. Medical Lett Drugs Ther 2021;63:160.
- 5.↵
In this issue
The Journal of Rheumatology
Vol. 49, Issue 5
1 May 2022
Baricitinib for Refractory Eosinophilic Fasciitis: Myth or Reality?
Gang Wang, Ning Zhuo, Jingyang Li
The Journal of Rheumatology May 2022, 49 (5) 546-547; DOI: 10.3899/jrheum.211126